AskBio owns and operates a cell line manufacturing process and an extensive capsid library and has generated hundreds of proprietary third generation gene vectors. AskBio’s double strand adeno-associated virus vectors (AAV) have a low effective dose, more cell type specificity and less potential systemic effects. AskBio’s proprietary production line requires fewer resources and regulatory steps and has been used in seven clinical-grade productions, over 50 preclinical lots and over 4,000 grade lots.